Jacobio Pharmaceuticals
加科思
Executive Summary
Jacobio is a Beijing-based, Hong Kong-listed oncology biotech founded by BeiGene co-founder Yinxiang Wang, with strong credibility in RAS-targeted cancer therapies. The company has proven deal-making capability, evidenced by their successful KRAS G12C inhibitor (JAB-21822) licensing to AbbVie for ex-China rights. With clear BIOSECURE status and an experienced leadership team, Jacobio represents a lower-risk Chinese biotech partnership opportunity for US pharma. Their focus on difficult-to-drug targets like RAS proteins aligns well with major pharma strategic priorities.
Structure: As a Hong Kong-listed company (1167.HK), Jacobio likely operates through a typical VIE structure with Beijing operations controlled through contractual arrangements by a Hong Kong holding entity. The Hong Kong listing provides additional transparency and regulatory oversight compared to purely mainland Chinese entities, which should facilitate due diligence processes for US acquirers.
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
Yinxiang Wang 王印祥 | Founder, Chairman & CEO | PhD; Former co-founder of BeiGene |
Ownership & Shareholder Structure
Clinical Trials(12 total)
3
Phase 1
9
Phase 1, Phase 2
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06973564 | JAB-23E73, JAB-23E73, JAB-23E73 | Ph.1, Ph.2 | RECRUITING | 294 |
| NCT06959615 | JAB-23E73, JAB-23E73 | Ph.1, Ph.2 | RECRUITING | 334 |
| NCT06386146 | JAB-30355, JAB-30355 | Ph.1, Ph.2 | RECRUITING | 144 |
| NCT05490472 | JAB-2485 (Aurora A inhibitor), JAB-2485 (Aurora A inhibitor) | Ph.1, Ph.2 | RECRUITING | 102 |
| NCT05174585 | JAB-BX102 (anti-CD73 monoclonal antibody), pembrolizumab (anti-PD-1 monoclonal antibody) | Ph.1, Ph.2 | COMPLETED | 21 |
| NCT05002270 | JAB-21822 (KRAS G12C inhibitor), JAB-21822 (KRAS G12C inhibitor), JAB-21822 (KRAS G12C inhibitor), Cetuximab (EGFR inhibitor) | Ph.1, Ph.2 | COMPLETED | 29 |
| NCT04686682 | JAB-8263, JAB-8263 | Ph.1, Ph.2 | RECRUITING | 152 |
| NCT04721223 | JAB-3068, PD1 inhibitor | Ph.1, Ph.2 | COMPLETED | 12 |
| NCT04587479 | JAB-8263 | Ph.1 | COMPLETED | 41 |
| NCT04045496 | JAB-3312 | Ph.1 | COMPLETED | 40 |
| NCT03565003 | JAB-3068 | Ph.1, Ph.2 | COMPLETED | 126 |
| NCT03518554 | JAB-3068 | Ph.1 | COMPLETED | 38 |
BIOSECURE Risk
Company has clear BIOSECURE status with no BCC designation, and Hong Kong listing structure provides additional regulatory distance from mainland Chinese government influence
Key Exposures:
- •Beijing headquarters and likely R&D operations subject to Chinese data security laws
- •Potential future political risk if US-China tensions escalate
Mitigation: Hong Kong listing structure and clear BIOSECURE status provide natural mitigation; no additional company-specific actions identified
BD Intelligence
Therapeutic Areas:
Recent Deals: Successfully licensed JAB-21822 (KRAS G12C inhibitor) to AbbVie for ex-China rights, demonstrating strong deal execution capability and validation of their RAS-focused platform
Approach: Direct CEO-level engagement with Yinxiang Wang given his BeiGene pedigree and proven track record; focus on additional RAS program opportunities and platform technology licensing
Red Flags
- ⚠Limited public information on pipeline beyond lead KRAS program
- ⚠Dependency on single founder/CEO for strategic direction
- ⚠Beijing HQ location creates ongoing geopolitical monitoring requirement
Quick Facts
- Key People
- 1
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 12
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (12 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.